Dr Reddy’s Laboratories is currently trading at Rs. 1673.00, up by 27.60 points or 1.68% from its previous closing of Rs. 1645.40 on the BSE.
The scrip opened at Rs. 1640.00 and has touched a high and low of Rs. 1676.00 and Rs. 1640.00 respectively. So far 44231 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1818.00 on 20-Apr-2012 and a 52 week low of Rs. 1387.00 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 1676.00 and Rs. 1603.00 respectively. The current market cap of the company is Rs. 28340.94 crore.
The promoters holding in the company stood at 25.57% while Institutions and Non-Institutions held 40.32% and 17.32% respectively.
Dr Reddy’s Laboratories - wholly owned subsidiary - Quimicas Falcon de Mexico SA de C.V., the company’s manufacturing facility located at Cuernavaca in Mexico’s import alert has been lifted. Dr. Reddy’s has received a clearance from the United States Food and Drug Administration (USFDA) on July 26, 2012.
The company’s Mexico facility was inspected by USFDA in November 2010. Based on observations by the USFDA, a Warning Letter was shared on June 14, 2011 with the company. The company worked with USFDA to resolve the observations in the Warning Letter.
Further, an inspection report after the last inspection from March26 - 30, 2012 indicated that USFDA are satisfied with all the outstanding action points that the company has submitted.
With the satisfactory closure of observations in the warning Letter and the lifting of the import alert, Dr. Reddy’s can now start importing products to the US from this facility. The Mexico facility produces Intermediates and Active Pharmaceutical Ingredients.
Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1814.50 |
| Dr. Reddys Lab | 1340.80 |
| Cipla | 1476.45 |
| Lupin | 2160.20 |
| Zydus Lifesciences | 972.95 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
